Market LIVE
Published markets; coverage varies by country
Product profile · United States

Tysabri

 ·  Patent Litigation & Settlement History ↓

Ingredientnatalizumab
Application typeBLA
Application125104
Product001
Dosage formInjection
RouteIntravenous
Strength300MG/15ML (20MG/ML)
Approval date2004-11-23
Marketing statusRx
Status event—
ApplicantBiogen Inc.
Product source

Current GenericRadar decision

Year2017
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typePATENT
Anchor date2017-04-27
Patent anchor2017-04-27
Exclusivity anchor2016-11-23
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2017. Anchor type: PATENT. Patent anchor: 2017-04-27. Exclusivity anchor: 2016-11-23. Anchor date: 2017-04-27. Patent tail: not established. Exclusivity tail: not established. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
71572762024-06-21PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
77591172024-06-21PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
107050952026-04-04PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
97095752026-04-04PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
88714492026-04-12PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
102332452027-02-28PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
112928452027-02-28PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
94935672027-03-05PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
81243502027-08-02PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
96963072030-02-05PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
90059262030-10-01PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
92123792030-11-28PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
90968792031-01-07PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
104442342031-01-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
112874232031-01-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
83184162031-01-20PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
103087062031-02-05PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
88090492031-05-22PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
91090152031-08-13PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
93166412032-01-09PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
105904542032-05-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
97905332032-05-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
95622522033-05-11PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
101199762034-05-27PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
106778032034-05-27PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
112807942034-05-27PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
106767722034-08-19PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
99949682034-08-19PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
100238312035-03-17PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
111247602035-08-27PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
112681192036-02-21PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———
108444162036-06-01PURPLE_BOOK ————
Original PB source record retained in gnr_patent_source_records. No TRUE_DS/DS-equivalent judgment.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
761322 / 001BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-08-24—Sandoz Inc.NREFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
761322 / 001Sandoz Inc.BIOSIMILAR_APPROVAL · BIOSIMILAR_APPROVED2023-08-24 REFERENCE_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
BLA_PATENT_EXCLUSIVITY_REVIEW—BUSINESS_CLASSIFICATION_WITH_CONDITIONSEnglish description not available.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.